In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
We are pleased to announce the launch of UTIPRO® PLUS, our product for uncomplicated UTIs, in Finland.
The product is commercialized over the Finnish territory under the umbrella brand UrinCUR / Utipro plus and it is distributed by RFSU, our partner for the product on the Swedish and Norwegian territory as well.
For the fourth consecutive year, Noventure was present at the annual congress of the EAU - European Association of Urology- that took place in Barcelona 15th – 19th March 2019.
Noventure participation to EAU is to confirm its presence in the urology field with its medical device for oral use UTIPRO PLUS intended to control and prevent uncomplicated UTIs.
Disruption of the epithelial barrier function has been recently associated with a variety of diseases, mainly at intestinal level, but also affecting the respiratory epithelium and other mucosal barriers. Non-pharmacological approaches such as xyloglucan, with demonstrated protective barrier properties, are proposed as new alternatives for the management of a wide range of diseases, for which mucosal disruption and, particularly, tight junction alterations, is a common characteristic.
